Once-weekly Altuviiio, a new kind of factor VIII therapy for haemophilia A that provides considerable bleed prevention, has been approved by the US FDA.

Once-weekly Altuviiio, a new kind of factor VIII therapy for haemophilia A that provides considerable bleed prevention, has been approved by the US FDA.

Altuviiio [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly known as efanesoctocog alfa, is a first-in-class, highly sustained factor VIII replacement therapy that has received FDA approval. For both adults and children with haemophilia A, the use of altuviiio is recommended…